DynaMed. Any time, An y w here

Similar documents
Supporting the IOM s Recommendations for the Future of Nursing

Articles Presented. Journal Presentation. Dr Albert Lo. Dr Albert Lo

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

S1. Which of the following age categories do you fall into? Please select one answer only years of age years of age years of age

Elsevier ClinicalKey TM FAQs

Hypertension Best Practices Symposium

Lesson Outline Outline

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis

DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE DRUGS IN DIABETIC PATIENTS WITH CKD

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

ClinicalKey User Guide Edition 2.0

Radiology Business Management Association Technology Task Force. Sample Request for Proposal

Assessing the effectiveness of medical therapies finding the right research for each patient: Medical Evidence Matters

New Oral AntiCoagulants (NOAC) in 2015

AT&T Global Network Client for Windows Product Support Matrix January 29, 2015

Cardiovascular Risk in Diabetes

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

Max Planck Encyclopedia of Public International Law User Guide.

Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS

Atrial Fibrillation: Drugs, Ablation, or Benign Neglect. Robert Kennedy, MD October 10, 2015

Demonstrating Meaningful Use Stage 1 Requirements for Eligible Providers Using Certified EMR Technology

Clinical Audit in Hospital Authority. Dr Betty Young Convenor for Clinical Audit, Hospital Authority

HYPERTENSION ASSOCIATED WITH RENAL DISEASES

Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo

Clinical Quality Measure Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW

Ruchika D. Husa, MD, MS Assistant t Professor of Medicine in the Division of Cardiology The Ohio State University Wexner Medical Center

Trends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins

Earning and Redeeming CME/CE Credit

SEARCH The Health Sciences Library Manipal University, Manipal. Library e-resources

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

304 Predictive Informatics: What Is Its Place in Healthcare?

Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

Roux-en-Y Gastric Bypass

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*

HSE SOUTH EAST LIBRARY SERVICE CLINICAL KEY: USER GUIDE

Antiaggreganti. STEMI : cosa c è di nuovo? Heartline Genova Novembre 2015

New Oral Anticoagulants

Research Skills for Non-Researchers: Using Electronic Health Data and Other Existing Data Resources

DATE: 29 August 2012 CONTEXT AND POLICY ISSUES

Table 1 Performance Measures. Quality Monitoring P4P Yr1 Yr2 Yr3. Specification Source. # Category Performance Measure

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Performance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis

Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8)

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

UpToDate. Understanding Clinical Decision Support. Janet Broome Sales Manager, UK, Ireland and Italy

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast

EMR Tutorial Acute Coronary Syndrome

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus

How do you decide on rate versus rhythm control?

Everything you ever wanted to know about. Physiotherapy. C a n a d a ONLINE

The Anti coagulated Patient: The Cardiologist s View. February 28, 2015

U.O.C. Ortognatodonzia Area Funzionale Omogena di Odontoiatria

Does Depression affect compliance with CPAP therapy in patients with Obstructive Sleep Apnea? Ramesh Metta, MBBS M Jeffery Mador, MD

Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements

Anticoagulation For Atrial Fibrillation

DATE: 06 May 2013 CONTEXT AND POLICY ISSUES

NUVIGIL (armodafinil) oral tablet

Emergency Department Callbacks. By Ronald A. Hellstern, MD, Chief Medical Officer, Loopback Analytics

NewsEdge.com User Guide

11/2/2015 Domain: Care Coordination / Patient Safety

Protective Effects of Propranolol in Adults Following Severe Burn Injury: A Safety and Efficacy Trial!

Earning, Redeeming and Merging CME/CE/CPD Credit

Case 2:08-cv ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8

Improving Evidence-Based Primary Care for Chronic Kidney Disease. Walter L. Calmbach MD MPH South Texas Ambulatory Research Network (STARNet)

Guidelines for the management of hypertension in patients with diabetes mellitus

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Carolina s Journey: Turning Big Data Into Better Care. Michael Dulin, MD, PhD

CENTERPOINT ENERGY TEXARKANA SERVICE AREA GAS SUPPLY RATE (GSR) JULY Small Commercial Service (SCS-1) GSR

International Hospital Inpatient Quality Measures

Westlaw China Online Legal Database Structure

Guidance for Industry Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims

ESCMID Online Lecture Library. by author

Transcription:

DynaMed Access DynaMed Any time, An y w here

DynaMed DynaMed is a clinical reference tool created by physicians for physicians and other health care professionals for use at the point-ofcare. With thousands of topics, DynaMed is an indispensable resource for answering clinical questions during practice. DynaMed balances the latest content and resources with validity, relevance and convenience to create the most useful clinical resource possible. Updated daily, DynaMed applies a 7-step systematic evidencebased process to all of its content, assuring that the science backing the conclusions is sound. Why Would I Use DynaMed? A product of EBSCO Health Improve health outcomes and reduce health care costs by using the best available evidence for clinical decision-making Quickly obtain pertinent information right at the point-of-care Keep abreast of the latest medical research with daily updates through DynaMed s Systematic Literature Surveillance Earn Continuing Medical Education (CME) credits How Do I Access DynaMed? You can access DynaMed from workstations throughout your institution and from your mobile device. (Contact your administrator for details about how to take advantage of mobile access.) Use the information below to log in to DynaMed remotely. Access URL: User Name: Password: Help Contact: Content information on reverse side...

Content, eatures & unctionality at a Glance... 1 2 3 4 5 6 Easy, Powerful Searching Search by keyword or browse alphabetically by specific topic or by category Content Spotlight Content in this section is updated frequently to highlight clinically relevant news and information Evidence-Based Methodology View details on DynaMed s 7-step editorial process for determining the best available evidence Easily navigate to other relevant medical resources directly from DynaMed, including EBSCO databases (subscription required) Recent Updates Quickly view a list of the most recently updated topic summaries EBM ocus Newsletter Sign up for DynaMed s free newsletter to receive updates on timely and significant changes from articles most likely to change clinical practice. ree CME credit is available. 5 6 2 3 Spotlight DynaMed shown to be THE MOST CURRENT point-of-care reference (BMJ 2011 Sep 23) DynaMed 7-Step Evidence-Based Methodology Introducing Practice Changing Updates ST-elevation myocardial infarction (STEMI) updated with ESC/ACC/AHA/WH 2012 universal definition of MI (Eur Heart J 2012 Oct) Obstructive sleep apnea (OSA) in children updated with AAP recommendations (Pediatrics 2012 Sep) Streptococcal pharyngitis updated with IDSA recommendations (Clin Infect Dis 2012 Sep 9) DYNAMED WEEKLY UPDATE: Regular Aspirin Use After Diagnosis of Colorectal Cancer May Reduce Mortality in Patients with Tumor PIK3CA Mutation 1 Browse: A B C D E G H I J K L M N O P Q R S T U V W X Y Z EBSCO Support Site Online Privacy Policy Terms of Use Copyright 2012 EBSCO Industries, Inc. All Rights Reserved. 4 PERC LEXI-COMP Browse Categories NRC SMART IMAGEBASE

7 8 9 10 11 12 13 14 15 16 Hover unctionality Hover over a topic to see the full table of contents Linking Navigation Navigate directly to a topic section from the search result list Related Search Results View relevant search results from related EBSCO databases (subscription required) CME Earn continuing education credits Navigation View and select subsections of DynaMed topics for direct access to specific sections Comments to the Editor Send feedback directly to the DynaMed editorial team Search within Text Search for terms within the body text of topic summaries Level of Evidence Labeling Quickly discern the quality of evidence via easyto-interpret Level of Evidence labels Internal Topic Linking Easily jump to other related sections of a topic via embedded links ull Text Links Access ull Text medical Journals quickly and easily (subscription required). Get CME for this Topic + Related Summaries + General Information + Causes and Risk actors + Complications and Associated Conditions + History and Physical + Diagnosis Treatment Treatment Overview + Medications + Surgery and procedures ollow-up + Prognosis + Prevention and Screening + Quality Improvement + Guidelines and Resources Patient Information + ICD-9/ICD-10 Codes + References Patient Education Reference Center Send Comment to Editor 10 11 7 Result List 1 of 16 Expand All Collapse All A A A Search within text Result List 1 of 16 Expand All Collapse All A A A Search within text 13 mortality in 12% vs. 9% (p = 0.36) elective surgery for AAA in 20% vs. 26% (p = 0.11) cessation of study medication in 42.4% vs. 26.8% (p = 0.0002) withdrawal due to adverse effects 38% vs. 21% (NNH 6) Reference - J Vasc Surg 2002 Jan;35(1):72 in J Watch 2002 8 Mar 15;22(6):46 propranolol poorly tolerated and might increase mortality (level 2 [mid-level] evidence) based on small randomized trial with high dropout rate 54 patients with small AAA diagnosed on screening were randomized to propranolol 40 mg vs. placebo orally twice dailyvs. placebo for mean 2.5 years mortality in 16.7% vs. 4.2% (relative risk [RR] = 1.6, 95% CI 1.02-2.51) dropout rate 60% vs. 25% (RR = 1.74, 95% CI 1.06-2.86) ACE inhibitors: ACE inhibitors reported to be associated with reduced risk of ruptured AAA (level 3 [lacking direct] evidence) based on case-control study retrospective study of 15,326 patients > 65 years old admitted to hospital for AAAvs. placebo for mean 2.5 years 3,379 (22%) had ruptured AAA and 11,947 (78%) had intact AAA ACE inhibitor use reported in 665 (20%) with ruptured AAA vs. 2,761 (23%) with intact AAA (odds ratio 0.82, 95% CI 0.74-0.9) no statistically significant associations found for beta blockers, calcium channel blockers, alpha blockers, angiotensin receptor blockers, or thiazide diuretics Reference - Lancet 2006 Aug 19;368(9536):659 EBSCOhost ull Text editorial can be found in Lancet 2006 Aug 19;368(9536):622 EBSCOhost ull Text Am am Physician 2006 Nov 15;74(10):1780 Get CME for this Topic + Related Summaries + General Information + Causes and Risk actors + Complications and Associated Conditions + History and Physical + Diagnosis Treatment Treatment Overview + Medications + Surgery and procedures ollow-up + Prognosis + Prevention and Screening + Quality Improvement + Guidelines and Resources Patient Information + ICD-9/ICD-10 Codes + References Patient Education Reference Center Send Comment to Editor 9 mortality in 12% vs. 9% (p = 0.36) 14 elective surgery for AAA in 20% vs. 26% (p = 0.11) cessation of study medication in 42.4% vs. 26.8% (p = 0.0002) withdrawal due to adverse effects 38% vs. 21% (NNH 6) Reference - J Vasc Surg 2002 Jan;35(1):72 in J Watch 2002 Mar 15;22(6):46 propranolol poorly tolerated and might increase mortality (level 2 [mid-level] evidence) based on small randomized trial with high dropout rate 54 patients with small AAA diagnosed on screening were randomized to propranolol 40 mg vs. placebo orally twice dailyvs. placebo for mean 2.5 years mortality in 16.7% vs. 4.2% (relative risk [RR] = 1.6, 95% CI 1.02-2.51) dropout rate 60% vs. 25% (RR = 1.74, 95% CI 1.06-2.86) ACE inhibitors: ACE inhibitors reported to be associated with reduced risk of ruptured AAA (level 3 [lacking direct] evidence) based on case-control study retrospective study of 15,326 patients > 65 years old admitted to hospital for AAAvs. placebo for mean 2.5 years 3,379 (22%) had ruptured AAA and 11,947 15 (78%) had intact AAA ACE inhibitor use reported in 665 (20%) with ruptured AAA vs. 2,761 (23%) with intact AAA (odds ratio 0.82, 95% CI 0.74-0.9) no statistically significant associations found for beta blockers, calcium channel blockers, alpha blockers, angiotensin receptor blockers, or thiazide diuretics Reference - Lancet 2006 Aug 19;368(9536):659 EBSCOhost ull Text editorial can be found in Lancet 2006 Aug 19;368(9536):622 EBSCOhost ull Text Am am Physician 2006 Nov 15;74(10):1780 17 17 Create email alerts, print and email topic summaries, or generate persistent links to a topic 12 16

What will I find in DynaMed? One-click access to full-text articles Ability to earn CMEs Alerts when topics are updated Practice changing updates Clinical Calculators Guidelines Easy access from EMRs EBM ocus e-newsletter ICD-9 and ICD-10 codes EBSCO Industries, Inc. Printed in U.S.A. (1013) EBS-2758